Utilisation et incidence des agents biologiques à base d’anticorps monoclonaux durant la grossesse
Open Access
- 3 October 2021
- journal article
- review article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 193 (39), E1537-E1544
- https://doi.org/10.1503/cmaj.202391-f
Abstract
No abstract availableThis publication has 98 references indexed in Scilit:
- Safety of TNF-α inhibitors during IBD pregnancy: a systematic reviewBMC Medicine, 2013
- Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center studyScandinavian Journal of Gastroenterology, 2013
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- Effects of Discontinuing Anti–Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal ExposureClinical Gastroenterology and Hepatology, 2013
- Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapyInflammatory Bowel Diseases, 2011
- Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006Alimentary Pharmacology & Therapeutics, 2011
- High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancyAlimentary Pharmacology & Therapeutics, 2011
- Pregnancy outcomes after maternal exposure to rituximabBlood, 2011
- Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeedingRheumatology, 2010
- Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell DevelopmentJournal of Immunology Research, 2008